2nd Quarter - Report

BIOTECHNOLOGY INNOVATION ORGANIZATION for BIOTECHNOLOGY INNOVATION ORGANIZATION

Firm
Client
Income
—
Expenses
$3,500,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

15 issue areas, each in the filer's own words, with who lobbied on it and where.

Agriculture AGR

Climate Change ---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020 ---FY 2022 Appropriations ---Climate Risk Disclosures ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Fighting Climate Change through Biotechnology Innovation ---RFI from House Select Committee on the Climate Crisis Foreign Agricultural Biotechnology Laws and Regulations ---China Biotechnology Regulations ---EU Ag-Biotech Policies and Regulations ---Mexico Draft Decree Banning Genetically Modified Corn ---Mexico Import Approval Delays of Ag Biotech Funding for the USDA ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) Genetically Engineered (GE) Animals ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ------GE Salmon ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Efficient Science-Based Review of Biotech Products ---FDA Approvals, Guidance, & Regulations ---Labeling ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering Genetically Engineered (GE) Plants ---Climate Issues & impact on the agriculture, food, and forestry sectors ---EPA Regulatory Approach to Gene Editing Review and Labeling of Food Derived from Biotechnology ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ------GE Salmon ---Implementation of Disclosure Law USDA/APHIS Agricultural Biotechnology Regulations ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Regulatory Treatment of Gene Edited Products ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
JOSEPH DAMOND —
JEANNE HAGGERTY —
ERICK LUTT —
MICHAEL MATTOON —
MATTHEW O'MARA —

Contacted: Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Patent & Trademark Office (PTO); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Commerce, Dept of (DOC); Natl Security Council (NSC); Federal Trade Commission (FTC); White House Office; Health & Human Services, Dept of (HHS)

Bills named: H.R. 7393 (117th), S. 3894 (117th)

Health Issues HCR

21st Century Cures Act 2.0 ---House Discussion Draft ---RFI from House Energy and Commerce Committee 340B Drug Discount Program ---H.R.3203: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. ---Program Implementation & Oversight Biodefense Research, Development and Procurement Issues (Non-Funding) ---Executive Order on Modernizing Influenza Vaccines ---White House National Biodefense Strategy Biosimilars ---BSUFA Negotiations Coronavirus (COVID-19) Pandemic ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.869/S.289: Research Investment to Spark the Economy (RISE) Act of 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---COVID-19 Lessons Learned ---COVID-19 Pricing-Related Provisions ---COVID-19 Vaccine Distribution ---Defense Production Act (DPA) ---Drug Supply Chain Management ---Healthcare Disparities ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Medicare Reimbursement Policies ---Monoclonal Antibody Coverage and Utilization ---Patient Cost-Sharing and Smoothing ---PREP Act COVID-19 Declaration Coverage for Private Sector Procurement ---R&D Funding for Medical Countermeasures ---Senate HELP Pandemic Preparedness White Paper ---Supply Chain Issues ---TRIPS IP Waiver Diversity & Inclusion ---Clinical Trial Diversity Drug Evaluation and Review ---COVID-19 Lessons Learned ---Compassionate Use/Expanded Access ---Expedited Pathways ---FDA Hiring Flexibility ---FDA Management and Financial Accountability ---Patient-Focused Drug Development ---Prescription Drug User Fee Act (PDUFA) VII Priorities ---Priority Review Voucher Programs ---Promising Pathway Act (Discussion Draft) ---Regulatory Reform & Modernization ---Use of Real-World Evidence Drug Manufacturing, Quality & Distribution ---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft) ---Executive Order on Buy American ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---Lower Health Care Costs for Patients Act (Discussion Draft) ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) ---Restrictions on Intellectual Property Rights Drug Pricing ---FY 2022 Appropriations ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---CMMI Authority ---COVID-19 Pricing-Related Provisions ---Drug Pricing Provisions ---Prescription Drug Pricing Reduction Act (Discussion Draft) ---Reference Pricing in Drug Reimbursement ---Senate Finance Committee Drug Pricing Principles ---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft) Funding for Antimicrobial Resistance Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for FDA ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Prescription Drug User Fee Act (PDUFA) VI ---Prescription Drug User Fee Act (PDUFA) VII Priorities Funding for Health Resources and Services Administration (HRSA) ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 Funding for National Institutes of Health ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---Advanced Research Projects Agency for Health (ARPA-H) Funding for the Centers for Disease Control and Prevention Vaccine Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for 2020-2021 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic Medicaid ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021 ---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021 ---Pricing and Rebates ---Senate Finance Committee Drug Pricing Principles ---Value-Based Purchasing (VBP) Rule Reimbursement and Coverage of Innovative Products ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---CMMI Authority ---Drug Pricing Provisions ---Medicare Part B Physician-Administered Products ---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft) ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Reference Pricing in Drug Reimbursement ---Senate Finance Committee Drug Pricing Principles ---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft) ---Value-Based Purchasing (VBP) Rule ---Value-based Contracting and Communications Vaccines and Infectious Diseases ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.550: Immunization Infrastructure Modernization Act ---H.R.951: Maternal Vaccinations Act ---H.R.979: Vaccine Fairness Act ---H.R.1319: American Rescue Plan Act of 2021 ---H.R.1452: A bill to direct the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines, and for other purposes. ---H.R.1550: Promoting Resources to Expand Vaccination, Education, and New Treatments for (PREVENT) HPV Cancers Act of 2021 ---H.R.1978: Protecting Seniors through Immunizations Act ---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021 ---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021 ---H.R.3013: COVID Vaccine Transportation Access Act ---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021 ---H.R.3742: Vaccine Information for Nursing Facility Operators (INFO) Act ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---H.R.4127: A bill to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes. ---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 ---Adult Immunization ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Vaccine Injury Compensation Program ---Vaccine and Antimicrobial Resistance Product Development and Incentives Vaccine Injury Compensation Program ---FY 2022 Appropriations ---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021 ---H.R.3656: Vaccine Access Improvement Act of 2021

Contacted: White House Office; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); Commerce, Dept of (DOC); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); State, Dept of (DOS); SENATE; Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); Natl Security Council (NSC); Environmental Protection Agency (EPA); Food & Drug Administration (FDA); Natl Institutes of Health (NIH)

Bills named: H.R. 1978 (117th), H.R. 2873 (117th), H.R. 3743 (117th), H.R. 550 (117th), H.R. 133 (117th), H.R. 8920 (117th), H.R. 3013 (117th), H.R. 3 (117th), H.R. 3742 (117th), H.R. 1452 (117th), H.R. 4127 (117th), S. 2164 (117th), H.R. 3655 (117th), H.R. 979 (117th), H.R. 1319 (117th), H.R. 153 (117th), S. 581 (117th), S. 4760 (117th), H.R. 1550 (117th), S. 289 (117th), S. 1435 (117th), H.R. 2347 (117th), H.R. 3203 (117th), H.R. 869 (117th), H.R. 951 (117th), H.R. 2170 (117th), H.R. 3656 (117th), H.R. 2884 (117th), H.R. 19 (117th)

Energy/Nuclear ENG

Biofuels (Non-Funding) ---H.R.1113: Renewable Fuel Standard Integrity Act of 2021 ---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021 ---H.R.3440/S.2263: Sustainable Skies Act of 2021 ---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act ---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes. ---S.2118: Clean Energy for America Act of 2021 ---A Clean Fuel Standard or Low Carbon Fuel Standard ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Incentives for Sustainable Aviation Fuels ---Small Refinery Waivers ---Sustainable Aviation Fuels Tax Credit Biomass Programs (Non-Funding) ---Climate Issues & impact on the agriculture, food, and forestry sectors Biorefineries (Non-Funding) ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for FY 2022 ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Implementation of the Agriculture Improvement Act of 2018 Climate Change ---FY 2022 Appropriations ---S.1251/H.R.2820: Growing Climate Solutions Act of 2021 ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Fighting Climate Change through Biotechnology Innovation Funding for Biofuels, Biomass Crop Assistance, and Biorefineries ---FY 2022 Appropriations ---S.1260: United States Innovation and Competition Act of 2021 ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Incentives for Sustainable Aviation Fuels Renewable Fuel Standard (RFS) ---H.R.1113: Renewable Fuel Standard Integrity Act of 2021 ---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021 ---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act ---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes. ---A Clean Fuel Standard or Low Carbon Fuel Standard ---Cellulosic Registration Applications for Corn Kernel Fiber ---Climate Issues & impact on the agriculture, food, and forestry sectors ---RFS Reform ---Small Refinery Waivers

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
JEANNE HAGGERTY —
ERICK LUTT —
MICHAEL MATTOON —

Contacted: Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Natl Security Council (NSC); U.S. Trade Representative (USTR); SENATE; Agriculture, Dept of (USDA); White House Office; Office of Science & Technology Policy (OSTP); State, Dept of (DOS)

Bills named: S. 2118 (117th), H.R. 2820 (117th), S. 2263 (117th), S. 218 (117th), S. 193 (117th), H.R. 3440 (117th), S. 1251 (117th), H.R. 1512 (117th), H.R. 1113 (117th), S. 1260 (117th)

Trade (domestic/foreign) TRD

Digital Trade ---EU Digital Strategy Drug Pricing --- Reference Pricing in Drug Reimbursement Foreign Agricultural Biotechnology Laws and Regulations ---China Biotechnology Regulations ---EU Ag-Biotech Policies and Regulations ---Mexico Draft Decree Banning Genetically Modified Corn ---Mexico Import Approval Delays of Ag Biotech Intellectual Property International Enforcement ---China ---TRIPS Waiver The United States-Mexico-Canada Agreement (USMCA) ---Implementation of United States-Mexico-Canada Agreement (USMCA) ------Ag-Biotech Provisions ------IP Provisions ---Mexico Draft Decree Banning Genetically Modified Corn ---Mexico Import Approval Delays of Ag Biotech US-China Trade Agreement ---Ag-Biotech Provisions ---IP Provisions US-EU Trade Agreement ---Ag-Biotech Provisions World Trade Organization ---TRIPS Waiver ---United States Withdrawal from the World Trade Organization (WTO) World Health Organization (WHO) ---TRIPS Waiver ---United States Withdrawal from the World Health Organization (WHO)

Contacted: Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Natl Institutes of Health (NIH); SENATE; Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Agriculture, Dept of (USDA); State, Dept of (DOS); Natl Security Council (NSC)

Taxation/Internal Revenue Code TAX

Capital Formation Incentives ---H.R.2140/S.961: American Innovation Act ---H.R.3448: Helping Startups Continue to Grow Act ---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft) ---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft) ---Incentives for Sustainable Aviation Fuels ---Proposed amendments under the Exchange Act of 1934 ---Proposed amendments under the Investment Company Act of 1940 ---Proposed amendments under the Securities Act of 1933 Vaccine Injury Compensation Program ---H.R.3656: Vaccine Access Improvement Act of 2021

LobbyistCovered position, as disclosed
CAMERON ARTERTON —
KATHLEEN CALLANAN New —
ELIZABETH CARTIER ESHAM —
AIKEN HACKETT —
JEANNE HAGGERTY —
SHEA HARTLEY —
MICHAEL MATTOON —

Contacted: Patent & Trademark Office (PTO); Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Natl Security Council (NSC); White House Office; SENATE; U.S. Trade Representative (USTR); Agriculture, Dept of (USDA); Office of Science & Technology Policy (OSTP); State, Dept of (DOS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3448 (117th), H.R. 2140 (117th), S. 961 (117th), H.R. 3656 (117th)

Copyright/Patent/Trademark CPT

Antitrust Legislation ---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021 Bayh-Dole Act/Tech Transfer ---FY 2022 Appropriations ---Bayh-Dole Act ---March-In Rights ---NIST Proposed Rulemaking on Bayh-Dole Compulsory Licensing Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights Diversity in Patenting ---35 USC Section 101 on Patent Eligibility ---S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021 Drug Patenting ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---Lower Health Care Costs for Patients Act (Discussion Draft) ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) ---Restrictions on Intellectual Property Rights Intellectual Property Enforcement ---China ---General Patent Reform ---TRIPS Waiver Inter Partes Review ---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft) Patent Reform ---H.R.7259/S.2814: Patents for Humanity Program Improvement Act of 2020 ---S.1260: United States Innovation and Competition Act of 2021 ------Ownership and Assignments of Patents ---Patent Litigation Reforms Patenting of Biological Inventions ---35 USC Section 101 on Patent Eligibility ---DNA Patenting and Licensing ---Section 101 Modernization United States-Mexico-Canada Agreement (USMCA) ---Implementation of USMCA ------IP Provisions US-China Trade Agreement ---IP Provisions

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
MELISSA BRAND —
KATHLEEN CALLANAN New —
JOSEPH DAMOND —
AIKEN HACKETT —
JEANNE HAGGERTY —
DAVID LACHMANN —
MICHAEL MATTOON —
HANSJORG SAUER —

Contacted: Natl Security Council (NSC); SENATE; Agriculture, Dept of (USDA); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); White House Office; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); State, Dept of (DOS)

Bills named: H.R. 2884 (117th), H.R. 19 (117th), H.R. 153 (117th), S. 2164 (117th), S. 632 (117th), H.R. 7259 (117th), S. 2814 (117th), S. 1435 (117th), S. 1260 (117th), S. 225 (117th), H.R. 2873 (117th)

Small Business SMB

Capital Formation Incentives ---H.R.2140/S.961: American Innovation Act ---H.R.3448: Helping Startups Continue to Grow Act ---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft) ---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft) ---Incentives for Sustainable Aviation Fuels ---Proposed amendments under the Exchange Act of 1934 ---Proposed amendments under the Investment Company Act of 1940 ---Proposed amendments under the Securities Act of 1933 Capital Market Enhancements ---Accredited Investor Definition ---Amended Definition of Smaller Reporting Company ---Market Liquidity Proposals ---SEC Small Business Reform Sarbanes Oxley Section 404 (b) ---Small Issuer Exemption Short Selling Transparency

LobbyistCovered position, as disclosed
CAMERON ARTERTON —
KATHLEEN CALLANAN New —
ELIZABETH CARTIER ESHAM —
AIKEN HACKETT —
JEANNE HAGGERTY —
SHEA HARTLEY —
MICHAEL MATTOON —

Contacted: Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); Federal Trade Commission (FTC); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); State, Dept of (DOS); SENATE

Bills named: H.R. 2140 (117th), H.R. 3448 (117th), S. 961 (117th)

Medicare/Medicaid MMM

21st Century Cures Act 2.0 ---House Discussion Draft ---RFI from House Energy and Commerce Committee 340B Drug Discount Program ---H.R.3203: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. ---Program Implementation & Oversight Coronavirus (COVID-19) Pandemic ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---Patient Cost-Sharing and Smoothing Drug Manufacturing, Quality & Distribution ---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft) Drug Pricing ---FY 2022 Appropriations ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---CMMI Authority ---COVID-19 Pricing-Related Provisions ---Drug Pricing Provisions ---Prescription Drug Pricing Reduction Act (Discussion Draft) ---Reference Pricing in Drug Reimbursement ---Senate Finance Committee Drug Pricing Principles ---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft) Medicaid ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021 ---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021 ---Pricing and Rebates ---Senate Finance Committee Drug Pricing Principles ---Value-Based Purchasing (VBP) Rule Reimbursement and Coverage of Innovative Products ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---Administration Rebate Rule ---CMMI Authority ---Drug Pricing Provisions ---Medicare Part B Physician-Administered Products ---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft) ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Reference Pricing in Drug Reimbursement ---Senate Finance Committee Drug Pricing Principles ---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft) ---Step Therapy ---Value-Based Purchasing (VBP) Rule ---Value-based Contracting and Communications Vaccines and Infectious Diseases ---H.R.1978: Protecting Seniors through Immunizations Act ---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021 ---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021 ---H.R.4127: A bill to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes.

LobbyistCovered position, as disclosed
PHYLLIS ARTHUR —
KATHLEEN CALLANAN New —
AIKEN HACKETT —
JEANNE HAGGERTY —
MICHAEL MATTOON —
JOHN MURPHY —
JOEL STRAUS —

Contacted: Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE; State, Dept of (DOS); White House Office; Federal Trade Commission (FTC); Natl Security Council (NSC); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Agriculture, Dept of (USDA)

Bills named: H.R. 2170 (117th), H.R. 2347 (117th), S. 2164 (117th), H.R. 1978 (117th), H.R. 4127 (117th), H.R. 3 (117th), S. 581 (117th), H.R. 19 (117th), H.R. 3203 (117th)

Budget/Appropriations BUD

Coronavirus (COVID-19) Pandemic ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Antimicrobial Resistance (AMR) Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biofuels, Biomass Crop Assistance, and Biorefineries ---FY 2022 Appropriations ---S.1260: United States Innovation and Competition Act of 2021 ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Incentives for Sustainable Aviation Fuels Funding for FDA ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Prescription Drug User Fee Act (PDUFA) VI ---Prescription Drug User Fee Act (PDUFA) VII Priorities Funding for Health Resources and Services Administration (HRSA) ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 Funding for National Institutes of Health ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---Advanced Research Projects Agency for Health (ARPA-H) Funding for Renewable Chemicals/Bio-based Products ---FY 2022 Appropriations ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) Funding for the Centers for Disease Control and Prevention Vaccine Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for 2020-2021 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic Funding for the USDA ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ---Biotechnology and Agriculture Trade Program

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); State, Dept of (DOS); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); White House Office; Environmental Protection Agency (EPA); Office of Science & Technology Policy (OSTP); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Patent & Trademark Office (PTO); SENATE; U.S. Trade Representative (USTR)

Bills named: S. 4760 (117th), H.R. 3743 (117th), H.R. 133 (117th), H.R. 8920 (117th), H.R. 1319 (117th), S. 1260 (117th)

Chemicals/Chemical Industry CHM

Funding for Renewable Chemicals/Bio-based Products ---FY 2022 Appropriations ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) Renewable Chemicals/Bio-based Products (Non-Funding) ---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021 ---H.R.2532: Renewable Chemicals Act of 2021 ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Implementation of the Agriculture Improvement Act of 2018

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
JEANNE HAGGERTY —
ERICK LUTT —
MICHAEL MATTOON —

Contacted: Federal Trade Commission (FTC); Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); SENATE; Agriculture, Dept of (USDA); White House Office; Commerce, Dept of (DOC); Natl Security Council (NSC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Environmental Protection Agency (EPA)

Bills named: H.R. 2532 (117th), H.R. 1512 (117th)

Food Industry (safety, labeling, etc.) FOO

Genetically Engineered (GE) Animals ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ------GE Salmon ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Efficient Science-Based Review of Biotech Products ---FDA Approvals, Guidance, & Regulations ---Labeling ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering Review and Labeling of Food Derived from Biotechnology ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ------GE Salmon ---Implementation of Disclosure Law

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
JEANNE HAGGERTY —
ERICK LUTT —
MICHAEL MATTOON —

Contacted: Health & Human Services, Dept of (HHS); Natl Security Council (NSC); State, Dept of (DOS); Food & Drug Administration (FDA); Agriculture, Dept of (USDA); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); Natl Institutes of Health (NIH); White House Office; Environmental Protection Agency (EPA)

Animals ANI

Genetically Engineered (GE) Animals ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ------GE Salmon ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Efficient Science-Based Review of Biotech Products ---FDA Approvals, Guidance, & Regulations ---Labeling ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering Review and Labeling of Food Derived from Biotechnology ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ------GE Salmon ---Implementation of Disclosure Law

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
JEANNE HAGGERTY —
ERICK LUTT —
MICHAEL MATTOON —

Contacted: SENATE; Federal Trade Commission (FTC); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); State, Dept of (DOS); Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); Agriculture, Dept of (USDA); White House Office; Patent & Trademark Office (PTO); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); Commerce, Dept of (DOC)

Fuel/Gas/Oil FUE

Biofuels (Non-Funding) ---H.R.1113: Renewable Fuel Standard Integrity Act of 2021 ---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021 ---H.R.3440/S.2263: Sustainable Skies Act of 2021 ---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act ---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes. ---S.2118: Clean Energy for America Act of 2021 ---A Clean Fuel Standard or Low Carbon Fuel Standard ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Incentives for Sustainable Aviation Fuels ---Small Refinery Waivers ---Sustainable Aviation Fuels Tax Credit Biomass Programs (Non-Funding) ---Climate Issues & impact on the agriculture, food, and forestry sectors Biorefineries (Non-Funding) ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for FY 2022 ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Implementation of the Agriculture Improvement Act of 2018 Climate Change ---FY 2022 Appropriations ---S.1251/H.R.2820: Growing Climate Solutions Act of 2021 ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Fighting Climate Change through Biotechnology Innovation Funding for Biofuels, Biomass Crop Assistance, and Biorefineries ---FY 2022 Appropriations ---S.1260: United States Innovation and Competition Act of 2021 ---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House) ---Climate Issues & impact on the agriculture, food, and forestry sectors ---Incentives for Sustainable Aviation Fuels Renewable Fuel Standard (RFS) ---H.R.1113: Renewable Fuel Standard Integrity Act of 2021 ---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021 ---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act ---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes. ---A Clean Fuel Standard or Low Carbon Fuel Standard ---Cellulosic Registration Applications for Corn Kernel Fiber ---Climate Issues & impact on the agriculture, food, and forestry sectors ---RFS Reform ---Small Refinery Waivers

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
JEANNE HAGGERTY —
ERICK LUTT —
MICHAEL MATTOON —

Contacted: Natl Security Council (NSC); Office of Science & Technology Policy (OSTP); Natl Institutes of Health (NIH); Commerce, Dept of (DOC); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); White House Office; Environmental Protection Agency (EPA); Agriculture, Dept of (USDA); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1260 (117th), S. 1251 (117th), H.R. 1512 (117th), S. 218 (117th), S. 2118 (117th), S. 193 (117th), S. 2263 (117th), H.R. 1113 (117th), H.R. 2820 (117th), H.R. 3440 (117th)

Homeland Security HOM

Biodefense Research, Development and Procurement Issues (Non-Funding) ---Executive Order on Modernizing Influenza Vaccines ---White House National Biodefense Strategy Funding for Antimicrobial Resistance (AMR) Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
PHYLLIS ARTHUR —
KATHLEEN CALLANAN New —
AIKEN HACKETT —
JEANNE HAGGERTY —
MICHAEL MATTOON —
JOEL STRAUS New —

Contacted: SENATE; U.S. Trade Representative (USTR); State, Dept of (DOS); Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES; White House Office; Patent & Trademark Office (PTO); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Federal Trade Commission (FTC); Natl Security Council (NSC)

Bills named: S. 4760 (117th), H.R. 1319 (117th), H.R. 8920 (117th), H.R. 133 (117th)

Medical/Disease Research/Clinical Labs MED

Biodefense Research, Development and Procurement Issues (Non-Funding) ---Executive Order on Modernizing Influenza Vaccines ---White House National Biodefense Strategy Coronavirus (COVID-19) Pandemic ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Immunization Information Systems ---R&D Funding for Medical Countermeasures ---Senate HELP Pandemic Preparedness White Paper Funding for Antimicrobial Resistance (AMR) Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for National Institutes of Health ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---Advanced Research Projects Agency for Health (ARPA-H) Funding for the Centers for Disease Control and Prevention Vaccine Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for 2020-2021 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic

LobbyistCovered position, as disclosed
HAYLEY B ALEXANDER —
PHYLLIS ARTHUR —
KATHLEEN CALLANAN New —
AIKEN HACKETT —
JEANNE HAGGERTY —
MICHAEL MATTOON —
JOEL STRAUS New —

Contacted: Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); White House Office; Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); State, Dept of (DOS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Patent & Trademark Office (PTO); Office of Science & Technology Policy (OSTP); Agriculture, Dept of (USDA); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Natl Security Council (NSC); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 8920 (117th), H.R. 133 (117th), H.R. 3743 (117th), S. 4760 (117th), H.R. 1319 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.